NewAmsterdam notches another win in resurrection of Amgen cardio drug

A Dutch biotech loaded with hundreds of millions of dollars to resurrect an old Amgen drug has touted another mid-stage win for the cholesterol-lowering asset, and it will add another Phase III trial to the lineup.

NewAmsterdam Pharma said the CETP inhibitor, obicetrapib, cleared the ROSE2 trial, which tested obicetrapib...

Click to view original post